Physician profile
Michael Y Chan
NPI 1487660833
$296,513.55
in general payments reported to CMS, 2019-2025
42 companies · $64K in 2025
The $64K reported for 2025 was more than what 99% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $23K · 2020: $25K · 2021: $39K · 2022: $49K · 2023: $56K · 2024: $40K · 2025: $64K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $41K · Travel and Lodging: $32K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $31K · Honoraria: $23K · Food and Beverage: $19K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $15K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $40,500.00 |
| Travel and Lodging | $31,796.37 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $30,800.00 |
| Honoraria | $23,400.00 |
| Food and Beverage | $18,665.29 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $14,850.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $109,551.55 | 2019-2025 | Brilinta, Farxiga, Wainua |
| Shockwave Medical, INC | $80,317.57 | 2022-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Abbott Laboratories | $53,662.25 | 2019-2025 | Absolute Pro, Dragonfly Opstar, Coroflow Upgrade Kit |
| Abiomed | $33,084.31 | 2019-2025 | Impella |
| Philips North America LLC | $11,563.30 | 2019-2023 | (6574) Coronary Other |
| Novartis Pharmaceuticals Corporation | $1,496.18 | 2019-2025 | |
| Boston Scientific Corporation | $1,012.42 | 2020-2025 | Avvigo Guidance System, Wolverine Coronary Cutting Balloon, Crossboss |
| Medtronic, INC. | $857.20 | 2021-2025 | Linq II, Symplicity G3 |
| Recor Medical INC | $854.09 | 2024-2025 | Paradise Renal Denervation System, Paradise Ultrasound Renal Denervation System |
| Amgen INC. | $433.23 | 2019-2025 | Repatha, Repatha |
| Medtronic Vascular, INC. | $427.53 | 2019 | |
| Teleflex LLC | $402.98 | 2023-2024 | Turnpike, Guideliner |
| Janssen Pharmaceuticals, INC | $374.60 | 2019-2023 | Xarelto |
| Asahi Intecc USA, INC. | $312.10 | 2023-2024 | Asahi Ptca Guide Wire, Peripheral Vascular |
| Pfizer INC. | $294.08 | 2019-2024 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Chan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.